Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Jun 30, 2021 12:57pm
143 Views
Post# 33473719

RE:RE:RE:RE:RE:Earnings PR up

RE:RE:RE:RE:RE:Earnings PR up

I would not read anything in the late date except that the Financial Statements are under the responsibility of the CFO and I presume that he and Colussi the vp Finance are not yet geared up to go thru the preparation of the FS in a shorter time period..... 


SPCEO1 wrote: I would not expect the board to be proof reading relatively insignificant PR's about earnings announcements, but maybe somebody should be proof-reading any PR that goes out to make sure such silly, unforced errors don't happen. But given my track record on typos, I cannot really complain too much!!!

They are waiting about as long as they legally can to report which tells me they want to have the most info on the phase I available before they report, which is fine by me since that is the most relelvant info for the share price. Of course, I don't really think they will share much more than a few hints as to what the status of the phase I is but maybe we will be surprised. I am assuming they are reporting on Wednesday 7/14, but it could be they got the day rather than the date wrong.  
 

stephanedodier wrote: Same in the french version of the PR, each Financial PR is not reviewd by the board ?

annonce aujourd’hui qu’elle dvoilera, le mercredi 15 juillet 2021,




<< Previous
Bullboard Posts
Next >>